Renal and vascular physiology and phisiopathology
2024 Activity indicators
- 5 competitive public projects: ISCIII
- 1 private led project
- 4 competitive HR contracts
- 4 publications
- IF: 21.19
- Q1 publications: 3 (75%)
- 1 internationally supervised thesis read with a grade of Cum Laude
- 1 active patent
- Evaluators in different national agencies and public bodies: 5 researchers
Milestones
- Participation in the most important renal research consortia at the national level (RD21/0005/0023 RICORS2040 (KIDNEY DISEASE) and the Community of Madrid (P2022/BMD7221). New diagnostic and therapeutic strategies for chronic kidney disease.
- Continued generation of relevant knowledge in the field of the application of new materials to biomedicine (1 publication and 1 university contract).
- Launch of a collaborative project with a company (CDTI-ISCIII) focused on artificial intelligence: ALLPREVENT (PMPTA23/00033) "Prevention of serious pathological events in hemodialysis patients through continuous noninvasive monitoring of vital signs and analysis of circular biomarkers."
- Broad representation of group members as evaluators for national project funding agencies.
- Reading of a doctoral thesis, endorsed by publication of some of its results in a high-impact journal
Bibliometrics
| Articles | Accum. FI | Mean FI | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
|---|---|---|---|---|---|---|---|
| 2020 | 6 | 79.13 | 13.19 | 5 | 83 | 2 | 33 |
| 2021 | 13 | 81.62 | 6.28 | 12 | 92 | 5 | 38 |
| 2022 | 4 | 29.39 | 7.35 | 4 | 100 | 1 | 25 |
| 2023 | 4 | 27.30 | 6.83 | 4 | 100 | 1 | 25 |
| 2024 | 4 | 21.90 | 5.48 | 4 | 100 | 0 | 0 |
| 31 | 239.34 | 7.82 | 29 | 94 | 9 | 29 |
* Only original articles, editorials, guidelines and reviews
